{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T21:14:38Z","timestamp":1783718078807,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.clgc.2014.12.002","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T15:07:01Z","timestamp":1418137621000},"page":"287-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature"],"prefix":"10.1016","volume":"13","author":[{"given":"Vittorio","family":"Fusco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Saia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Paglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordana","family":"Bettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Scoletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bonacina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vescovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Merigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lo Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Guglielmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Di Fede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bedogni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2014.12.002_bib1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ctrv.2011.06.011","article-title":"Skeletal metastasis in renal cell carcinoma: current and future management options","volume":"38","author":"Wood","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2014.12.002_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2010.09.008","article-title":"Skeletal complications and survival in renal cancer patients with bone metastases","volume":"48","author":"Woodward","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.clgc.2014.12.002_bib3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/annonc\/mdr362","article-title":"Distribution of metastatic sites in renal cell carcinoma: a population-based analysis","volume":"24","author":"Bianchi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib4","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2014.12.002_bib5","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejca.2012.02.050","article-title":"Bisphosphonates combined with sunitinib may improve the response rate, progression-free survival and overall survival of patients with bone metastases from renal cell carcinoma","volume":"48","author":"Keizman","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2014.12.002_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nrendo.2010.195","article-title":"Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review","volume":"7","author":"Migliorati","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.clgc.2014.12.002_bib7","first-page":"1099","article-title":"Multinational Association of Supportive Care in Cancer (MASCC)\/International Society of Oral Oncology (ISOO). A systematic review of bisphosphonate osteonecrosis (BON) in cancer","volume":"18","author":"Migliorati","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clgc.2014.12.002_bib8","first-page":"533","article-title":"Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies","volume":"22","author":"Lee","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clgc.2014.12.002_bib9","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ejim.2013.05.011","article-title":"Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases","volume":"24","author":"Di Fede","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.clgc.2014.12.002_bib10","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.oraloncology.2009.10.004","article-title":"Osteonecrosis of the jaws induced by drugs other than bisphosphonates-a call to update terminology in light of new data","volume":"46","author":"Yarom","year":"2010","journal-title":"Oral Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib11","first-page":"c85","article-title":"Physiology and Pharmacology of Nonbisphosphonate Drugs Implicated in Osteonecrosis of the Jaw","volume":"78","author":"Troeltzsch","year":"2012","journal-title":"J\u00a0Can Dent Assoc"},{"key":"10.1016\/j.clgc.2014.12.002_bib12","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa)-induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2014.12.002_bib13","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systematic review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clgc.2014.12.002_bib14","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ajh.20481","article-title":"Osteonecrosis of the jaw associated with pamidronate therapy","volume":"81","author":"Zarychanski","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clgc.2014.12.002_bib16","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1200\/JCO.2005.01.7756","article-title":"Osteonecrosis of the jaws associated with bisphosphonate therapy","volume":"24","author":"Mignogna","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ejim.2006.10.008","article-title":"Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature","volume":"18","author":"Cavanna","year":"2007","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.clgc.2014.12.002_bib18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/annonc\/mdn788","article-title":"Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?","volume":"20","author":"Ayllon","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","article-title":"Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma","volume":"44","author":"Brunello","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.clgc.2014.12.002_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.clgc.2014.12.002_bib21","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/02841860802609574","article-title":"Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors","volume":"48","author":"Wolter","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000313680","article-title":"Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib","volume":"33","author":"Bozas","year":"2010","journal-title":"Onkologie"},{"key":"10.1016\/j.clgc.2014.12.002_bib23","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","article-title":"Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases","volume":"110","author":"Hoefert","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.clgc.2014.12.002_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/687043","article-title":"Bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma: a case series and review of the literature","author":"Agostino","year":"2010","journal-title":"Adv Urol"},{"key":"10.1016\/j.clgc.2014.12.002_bib25","first-page":"952","article-title":"Osteonecrosis of the jaws in patients assumine bisphosphonates and sunitinib: two case reports","volume":"16","author":"Agrillo","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.clgc.2014.12.002_bib26","first-page":"193","article-title":"Drug-induced palate osteonecrosis following nasal surgery","volume":"14","author":"Balmor","year":"2012","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.clgc.2014.12.002_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","article-title":"Osteonecrosis of the jaw related to sunitinib","volume":"15","author":"Koch","year":"2011","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2014.12.002_bib28","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2011.06.023","article-title":"Sunitinib-related osteonecrosis of jaw: a case report","volume":"113","author":"Flessig","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.clgc.2014.12.002_bib29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tripleo.2011.08.024","article-title":"Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications","volume":"113","author":"Nicolatou-Galitis","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.clgc.2014.12.002_bib30","unstructured":"MHRA. Bevacizumab and sunitinib: risk of osteonecrosis of the jaw. Drug Safety\u00a0Update 2011. Available at http:\/\/www.mhra.gov.uk\/Safetyinformation\/DrugSafetyUpdate\/CON105745. Accessed: January 2, 2015."},{"key":"10.1016\/j.clgc.2014.12.002_bib31","unstructured":"MHRA. Information sent to healthcare professionals in November about the safety of medicines (30 November 2010). Available at: http:\/\/www.mhra.gov.uk\/Safetyinformation\/Safetywarningsalertsandrecalls\/Safetywarningsandmessagesformedicines\/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines\/CON102775. Accessed: January 2, 2015."},{"issue":"suppl 1","key":"10.1016\/j.clgc.2014.12.002_bib32","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2014.12.002_bib33","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","article-title":"Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series","volume":"123","author":"Fedele","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.clgc.2014.12.002_bib34","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.joms.2008.02.012","article-title":"Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?","volume":"66","author":"Junquera","year":"2008","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2014.12.002_bib35","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.joms.2009.07.097","article-title":"American Association of Oral and Maxillfacial Surgeons position paper: bisphosphonate related osteonecrosis of the jaws- 2009 update: the need to refine the BRONJ definition","volume":"67","author":"Colella","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2014.12.002_bib36","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.joms.2008.09.031","article-title":"Sinus tracts\u2013an early sign of bisphosphonate-associated osteonecrosis of the jaws?","volume":"67","author":"Mawardi","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2014.12.002_bib37","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1601-0825.2012.01911.x","article-title":"Non-exposed bisphosphonate-related osteonecrosis of the jaw: a critical assessment of current definition, staging, and treatment guidelines","volume":"18","author":"Patel","year":"2012","journal-title":"Oral Dis"},{"key":"10.1016\/j.clgc.2014.12.002_bib38","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.oooo.2012.01.004","article-title":"Drug-related osteonecrosis of the jaws: \u201cExposure, or not exposure: that is the question.\u201d","volume":"113","author":"Mignogna","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.clgc.2014.12.002_bib39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1634\/theoncologist.2010-0183","article-title":"Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw","volume":"16","author":"Miksad","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2014.12.002_bib40","first-page":"3527","article-title":"Quality of life in breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients with head and neck cancer: a comparative study using the EORTC QLQ-C30 and QLQ-HN35 questionnaires","volume":"32","author":"Kyrgidis","year":"2012","journal-title":"Anticancer Res"},{"issue":"suppl 5","key":"10.1016\/j.clgc.2014.12.002_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"suppl 6","key":"10.1016\/j.clgc.2014.12.002_bib42","doi-asserted-by":"crossref","first-page":"vi164","DOI":"10.1093\/annonc\/mdm249","article-title":"New developments of aminobisphosphonates: the double face of Janus","volume":"18","author":"Santini","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib43","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hon.819","article-title":"Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells","volume":"25","author":"Allegra","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib44","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1756-8722-5-56","article-title":"Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw","volume":"5","author":"Vincenzi","year":"2012","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib45","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.oraloncology.2012.03.028","article-title":"Bisphosphonate-related osteonecrosis of the jaws\u2013a review","volume":"48","author":"Kuhl","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib46","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib47","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.joms.2008.11.015","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients","volume":"67","author":"Lazarovici","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2014.12.002_bib48","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00432-010-0953-1","article-title":"Outcome of treatment and parameters influencing recurrence in patients with bisphosphonate-related osteonecrosis of the jaws","volume":"137","author":"Mucke","year":"2011","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib49","doi-asserted-by":"crossref","first-page":"w13605","DOI":"10.4414\/smw.2012.13605","article-title":"Osteopathology of the jaw associated with bone resorption inhibitors: what have we learned in the last 8 years","volume":"142","author":"Jacobsen","year":"2012","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.clgc.2014.12.002_bib50","first-page":"672027","article-title":"Decreasing frequency of osteonecrosis of the jaw in cancer and myeloma patients treated with bisphosphonates: the experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy)","volume":"2013","author":"Fusco","year":"2013","journal-title":"ISRN Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib51","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib52","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib53","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2014.12.002_bib54","first-page":"1737","article-title":"Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab","volume":"22","author":"Fusco","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clgc.2014.12.002_bib55","unstructured":"Prati V, Ortega C, Aglietta M. (2011) Caso clinico di Osteonecrosi da inibitore di m-TOR. Abstract Convegno Osteonecrosi dei mascellari (ONJ): ruolo della Rete\u00a0Oncologica del Piemonte e della Valle d'Aosta Update 2011. Available at: http:\/\/www.reteoncologica.it\/images\/stories\/ONJ\/alessandria%20onj%202011-abstract.pdf (page 32). Accessed: January 2, 2015."},{"key":"10.1016\/j.clgc.2014.12.002_bib56","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.oooo.2013.02.001","article-title":"Osteonecrosis of the mandible associated with bevacizumab therapy","volume":"115","author":"Santos-Silva","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"suppl 2","key":"10.1016\/j.clgc.2014.12.002_bib57","first-page":"20","article-title":"Osteonecrosis of the jaw related to everolimus and bisphosphonates: a unique case report?","volume":"4","author":"Giancola","year":"2013","journal-title":"Ann Stomatol"},{"key":"10.1016\/j.clgc.2014.12.002_bib58","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.e15116","article-title":"Osteonecrosis of the jaw in patients treated with sunitinib and zoledronic acid (abstract e15116)","author":"Bozas","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib59","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/bjc.2012.385","article-title":"Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases","volume":"107","author":"Beuselinck","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2014.12.002_bib60","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.joms.2013.03.019","article-title":"Combination of zoledronic acid\u00a0and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma","volume":"71","author":"Smidt-Hansen","year":"2013","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2014.12.002_bib61","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1001\/jama.2013.282405","article-title":"Jaw lesion and discomfort","volume":"310","author":"Levin","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.clgc.2014.12.002_bib62","first-page":"3483","article-title":"Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24\u00a0months in patients with multiple myeloma or bone metastases from solid tumors","volume":"21","author":"Van den Wyngaert","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clgc.2014.12.002_bib63","first-page":"103","article-title":"BRONJ expert panel recommendation of the Italian Societies for Maxillofacial Surgery (SICMF) and Oral Pathology and Medicine (SIPMO) on bisphosphonate-related osteonecrosis of the jaws: risk assessment, preventive strategies and dental management","volume":"22","author":"Campisi","year":"2011","journal-title":"Ital J Maxillofac Surg"},{"key":"10.1016\/j.clgc.2014.12.002_bib64","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2217\/fon.13.211","article-title":"Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents","volume":"10","author":"Campisi","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2014.12.002_bib65","unstructured":"Bedogni A, Campisi G, Fusco V, et\u00a0al. Raccomandazioni clinico-terapeutiche sull'osteonecrosi delle ossa mascellari associata a Bisfosfonati e sua prevenzione. Societ\u00e0 Italiana di Chirurgia Maxillo-Facciale (SICMF). Presented at Societ\u00e0 Italiana di Patologia e Medicina Orale (SIPMO), Cleup Editrice, Padova, Italy. Available at: http:\/\/www.sipmo.it\/news\/raccomandazioni-clinico-terapeutiche-sullosteonecrosi-delle-ossa-mascellari-associata-a-bisfosfonati-e-sua-prevenzione. Accessed: January 2, 2015."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767314002626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767314002626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:23:47Z","timestamp":1761564227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767314002626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1558767314002626"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2014.12.002","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2014.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}